FIRST COMPREHENSIVE TREATMENT FOR ATOPIC · PDF filet a m i n s B 7, 3 a n d B 2 P E N Y ......
Transcript of FIRST COMPREHENSIVE TREATMENT FOR ATOPIC · PDF filet a m i n s B 7, 3 a n d B 2 P E N Y ......
![Page 1: FIRST COMPREHENSIVE TREATMENT FOR ATOPIC · PDF filet a m i n s B 7, 3 a n d B 2 P E N Y ... Vergés J. et al. Mejoría clínica y anatomopatológica de la psoriasis en pacientes con](https://reader031.fdocuments.net/reader031/viewer/2022030510/5aba1c767f8b9ad5338eb491/html5/thumbnails/1.jpg)
Scientifically protected skin
It provides relief for the skin and controls outbreaks in psoriasis and atopic dermatitis.
BIOIBERICA S.A., Pl. Francesc Macià, 7, 8ª planta. 08029 Barcelona (Spain). Tel. (+34) 93 490 49 08. www.bioiberica.com
TOPICAL AQUASORB and ORAL AQUASORB are complementary products that have greater therapeutic efficacy when used in combination.
Both products contain Chondroitin Sulfate. The administration of Chondroitin Sulfate by 2 routes helps to amplify and accelerate its effect.
Its combined administration provides the ingredients that have proven to be capable of recovering and maintaining the skin's balance with psoriasis and atopic dermatitis.
TOPICAL AQUASORBApply once or twice daily all over the body surface or to the specific areas to be treated.
ORAL AQUASORBTake 3 capsules a day, preferably in a single take and for three months. This period can be followed by a rest of 2 to 3 months, a�er which the regimen can be restarted and the same cycle followed.
FIRST COMPREHENSIVE TREATMENT FOR ATOPIC DERMATITIS AND PSORIASIS
Y30
550
0-0
715
![Page 2: FIRST COMPREHENSIVE TREATMENT FOR ATOPIC · PDF filet a m i n s B 7, 3 a n d B 2 P E N Y ... Vergés J. et al. Mejoría clínica y anatomopatológica de la psoriasis en pacientes con](https://reader031.fdocuments.net/reader031/viewer/2022030510/5aba1c767f8b9ad5338eb491/html5/thumbnails/2.jpg)
BIOIBERICA, S.A. is a biotechnological company that specialises in the research, development and distribution of high biological and therapeutic value biomolecules that contribute to improving people's quality of life.
HEPARINThe most used anticoagulant and antithrombotic medicinal product in the world. 1 in 5 doses of heparin is by Bioiberica.
FUNCTIONAL LIPIDSBioiberica produces functional lipids with beneficial properties in different health areas: dermatological, cognitive and metabolic.
CHONDROITIN SULFATE, GLUCOSAMINE AND HYALURONIC ACIDOne of our priorities is to improve the quality of life of the 200 million-plus patients in the world that suffer from osteoarthritis, articular lesions and other musculoskeletal disorders.
Bioiberica specialises in the prevention, diagnosis and treatment of joint health.
This specialisation leads us to continuously investigate new applications in other therapeutic areas.
Formulations studied to leverage all the beneficial effects of its ingredients, which have proven their capacity to recover and maintain the balance of altered skin.
Reduction of Episodes
It provides relief for the skin and controls outbreaks in psoriasis and atopic dermatitis.
ErythemaPruritusDesquamationHyperkeratosisDryness
Clinical Improvement
TOPICALAQUASORB
ORALAQUASORB
2 products:
SCIENCE IN BIOMOLECULES APPLIED TO DERMATOLOGY
![Page 3: FIRST COMPREHENSIVE TREATMENT FOR ATOPIC · PDF filet a m i n s B 7, 3 a n d B 2 P E N Y ... Vergés J. et al. Mejoría clínica y anatomopatológica de la psoriasis en pacientes con](https://reader031.fdocuments.net/reader031/viewer/2022030510/5aba1c767f8b9ad5338eb491/html5/thumbnails/3.jpg)
How does AQUASORB act in Psoriasis and Atopic Dermatitis?
· IT CONTROLS CLINICAL EPISODES· IT REDUCES THEIR FREQUENCY· IT MAKES IT POSSIBLE TO REDUCE DRUG DOSES
Ingredients with proven clinical efficacy
· 100% natural ingredients with a high safety profile
· No side effects and compatible with other treatments
· BIOIBERICA guarantees the maximum quality of its active ingredients
ACTION IN PSORIASIS AND ATOPIC DERMATITIS
· Highly-pure concentrated fatty acids.· Environmentally sustainable, endorsed by the Friends of the Sea Association
Chondroitin
Sulfate Sphingolipids (ceramide and sphingomyelin)
Hyaluronic Acid
Vitamins B7, B3 and B2
Om
ega
3
HYPERKERATOSIS DESQUAM
ATIO
N
DRYNESS PRURITUS
ERYT
HEM
A
PureMaxTM is a trade mark of Croda International Plc. England
BENEFITS Sphingolipids(ceramide and sphingomyelin)
Omega 3Vitamins
B7, B3 & B2Hyaluronic
Acid
Reduces skin inflammation
Stimulates endogenoussynthesis of ceramides
Improves skinhydration
Reduces skinirritation
Improves clinicaloutcome
Controls pruritus
Chondroitin Sulfate
NEW INGREDIENTS IN DERMATOLOGY
![Page 4: FIRST COMPREHENSIVE TREATMENT FOR ATOPIC · PDF filet a m i n s B 7, 3 a n d B 2 P E N Y ... Vergés J. et al. Mejoría clínica y anatomopatológica de la psoriasis en pacientes con](https://reader031.fdocuments.net/reader031/viewer/2022030510/5aba1c767f8b9ad5338eb491/html5/thumbnails/4.jpg)
It reduces the signs of psoriasis (n=129)
The administration of CS for 3 months delivers a statistically significant reduction in the signs of psoriasis.
Reduction in the intensity of psoriasis a�er 3 months of treatment.
Days00
5
10
15
20
25
30
35
30 60 90
Patie
nts w
ith p
lant
ar p
soria
sis (%
)
Placebo Chondrotin sulfate
Möller I. et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage. 2010;18 Suppl 1:S32-40.
Clinical and histological improvement in psoriatic plaques in 91% of the casesSecond clinical case performed with 11 patients with osteoarthritis and psoriasis concomitantly
Epidermis thickness before treatment.
54% reduction in the total thickness of the epidermis treated for two months with chondroitin sulfate.
Vergés J. et al. Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. Dermatol Online J. 2005 Mar 1;11(1):31.
The administration of CS B BIOACTIVE achieves an outstanding clinical and histological clinical benefit in psoriatic lesionsFirst clinical case carried out with 3 patients with osteoarthritis and psoriasis concomitantly
Vergés J. et al. Mejoría clínica y anatomopatológica de la psoriasis en pacientes con artrosis tratados con condroitín sulfato: descripción de 3 casos. Med Clin 2004; 123(19):739-742.
Before treatment A�er treatment Before treatment A�er treatment
74% reduction in keratinocytes (Ki-67) cell proliferation rate in a 57-year-old patient treated with 800mg/day of
chondroitin sulfate for 2 months.
54% reduction in total epidermis thickness in a 67-year-old patient treated for 2 months with 800mg/day of chondroitin sulfate.
SCIENCE IN PSORIASIS AND ATOPIC DERMATITIS
It reduces skin inflammation
· Psoriasis and atopic dermatitis have an important inflammatory component.· In patients with psoriasis, there is a deregulation of NF-kB that leads to a pro-inflammatory condition.· CS reduces the translocation of NF-kB and consequently reduces skin inflammation.· CS presents an excellent safety profile
Souich P. et al. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cel Mol Med 2009; 13(8A): 1451-1463
p50 p65p38 MAPK
Erk 1/2H2O2/O2
IL-1R
CSCS
CS
S276S536
p50 p65 mARN
PROTEOLYTIC ENZYMES
PRO-INFLAMMATORY ENZYMES
PRO-INFLAMMATORYCYTOKINES
MMP-3MMP-9MMP-13Catepsina B
PLA2, COX-2NOS-2
TNF-αIL-1ß
Mechanism of action of Chondroitin Sulfate
Chondroitin Sulfate
![Page 5: FIRST COMPREHENSIVE TREATMENT FOR ATOPIC · PDF filet a m i n s B 7, 3 a n d B 2 P E N Y ... Vergés J. et al. Mejoría clínica y anatomopatológica de la psoriasis en pacientes con](https://reader031.fdocuments.net/reader031/viewer/2022030510/5aba1c767f8b9ad5338eb491/html5/thumbnails/5.jpg)
Reduces skin inflammation
Omega 3 (EPA and DHA)It stimulates the endogenous synthesis of ceramides, improving the skin's lipid structure and composition.
Skin moisturisation and elasticity
Hyaluronic Acid
· The oral administration of omega-3 fatty acids complements the topical treatment of psoriasis, significantly contributing to a reduction in pruritus, erythema and desquamation in the affected areas. BIOSFEEN contains sphingomyelin, which has a
dose-dependent inhibition effect on the synthesis of PGE2 in an in vitro keratinocyte model.
In atopic dermatitis, there is a reduction in the content of skin ceramides that compromises the epidermis's barrier function.
The application of the BIOSFEEN sphingolipid extract stimulates the endogenous synthesis of ceramides.
Improvement in the skin's lipid structure and composition.
Hyaluronic acid is a glycosaminoglycan present in the epidermis, and one of the main components of the extracellular matrix. It has a high water retention capacity and has been proven to play a central role in skin moisturisation and elasticity.
Price RD. et al. Hyaluronic acid: the scientific and clinical evidence. J Plast Reconstr Aesthet Surg. 2007;60 (10):1110-1119.
Mason F. Skin hydration and hyaluronic acid. Ann Dermatol Venereol 2010;137 Suppl 1:S23-S25.
· Supplementation with DHA led to an increase in omega-3 plasma concentration, resulting in a clinical improvement of atopic eczema determined by a reduction in the SCORAD index.
Keratinocyte culture
Control Sphingomyelin
Con
cent
ratio
n of
PG
E 2
SCIENCE IN PSORIASIS AND ATOPIC DERMATITIS
Cerrato S et al. Effects of sphingolipid extracts and glycosaminoglycans on morphological structure and lipid content in an in vitro canine skin model. Veterinary Dermatology 2015; 26:299.
Internal Data
Koch C et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. Br J Dermatol 2008;158(4):786-792.
Sphingolipids
BjØrneboe A et al. Effect of n-3 fatty acid supplement to patients with atopic dermatitits. J Intern Med Suppl. 1989;731:233-236.
Mayser et al. A double-blind, randomized, placebo-controlled trial of n=3 versus n=6 fatty acid-based lipid infusion in atopic dermatitis. JPEN J Parenter Enteral Nutr. 2002;26(3):151-158.
75% reduction in inflammation
![Page 6: FIRST COMPREHENSIVE TREATMENT FOR ATOPIC · PDF filet a m i n s B 7, 3 a n d B 2 P E N Y ... Vergés J. et al. Mejoría clínica y anatomopatológica de la psoriasis en pacientes con](https://reader031.fdocuments.net/reader031/viewer/2022030510/5aba1c767f8b9ad5338eb491/html5/thumbnails/6.jpg)
Study to evaluate Aquasorb's efficacy in patients with dermal alterationsPrincipal investigator: Montse Pérez MD (Clínica Moragas)
· The improvement in global clinical index is 78%.
· In 80% of the patients, there is an improvement in the degree of desquamation, erythema, pruritus, hyperkeratosis and fissures and/or cracks.
· The improvement in global clinical index is 78%.
· Pruritus and erythema are significantly reduced in all patients
0%10%20%30%40%50%60%70%80%90%
100%
Initial
Degree ofdesquamatión
Degree oferythema
Degree ofpruritus
Degree ofhyperkeratosis
Degree of fissures/cracks
Final Initial Final Initial Final Initial Final Initial Final
Initial
Degree ofdesquamatión
Degree oferythema
Degree ofpruritus
Degree ofhyperkeratosis
Degree of fissures/cracks
Final Initial Final Initial Final Initial Final Initial Final
Very severe
Severe
Moderate
Mild
Null
Very severe
Severe
Moderate
Mild
Null
0%10%20%30%40%50%60%70%80%90%
100%
EFFICACY IN PSORIASIS AND ATOPIC DERMATITIS
PATIENTS WITH PSORIASIS
PATIENTS WITH ATOPIC DERMATITIS
PSORIASIS ATOPIC DERMATITIS
Degree of hyperkeratosis (0-4)
Degree of fissures/cracks (0-4)
Degree of pruritus (0-4)
Degree of erythema (0-4)
Degree of desquamation (0-4)
Baseline Mass Index (0-20)
Body Mass Index
Age
Sex (Men/Women) (%)
3
2
2
2
1
50±5,2
26±1,8
10±0,5
50/50
DesquamationErythemaPruritusHyperkeratosisFissures/Cracks
Effect of AQUASORB on the clinical symptoms of dermal alterations using the following parameters in 18 patients with psoriasis or atopic dermatitis:
It provides relief for the skin and controls outbreaks in psoriasis and atopic dermatitis.
2
2
3
1
1
25±1,3
47±5,3
8±0,3
25/75